JP2019521192A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019521192A5 JP2019521192A5 JP2019520937A JP2019520937A JP2019521192A5 JP 2019521192 A5 JP2019521192 A5 JP 2019521192A5 JP 2019520937 A JP2019520937 A JP 2019520937A JP 2019520937 A JP2019520937 A JP 2019520937A JP 2019521192 A5 JP2019521192 A5 JP 2019521192A5
- Authority
- JP
- Japan
- Prior art keywords
- oxo
- alkyl
- dihydrothieno
- pyrimidine
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 12
- 206010019280 Heart failures Diseases 0.000 claims 11
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- LBSSCTYABOXXHX-UHFFFAOYSA-N 2-(cyclopenten-1-ylmethyl)-5-methyl-4-oxo-3h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1C(=O)C=2C(C)=C(C(O)=O)SC=2N=C1CC1=CCCC1 LBSSCTYABOXXHX-UHFFFAOYSA-N 0.000 claims 2
- SKVLWSYDTSHFQY-UHFFFAOYSA-N 2-[(3,4-dichlorophenyl)methyl]-5-methyl-4-oxo-3h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1C(=O)C=2C(C)=C(C(O)=O)SC=2N=C1CC1=CC=C(Cl)C(Cl)=C1 SKVLWSYDTSHFQY-UHFFFAOYSA-N 0.000 claims 2
- REQCEJMBROBVOU-UHFFFAOYSA-N 2-[(3-chloro-4-fluorophenyl)methyl]-5-methyl-4-oxo-3h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1C(=O)C=2C(C)=C(C(O)=O)SC=2N=C1CC1=CC=C(F)C(Cl)=C1 REQCEJMBROBVOU-UHFFFAOYSA-N 0.000 claims 2
- OHWZRDHRORANHY-UHFFFAOYSA-N 2-[(3-chlorophenyl)methyl]-4-oxo-3h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound S1C(C(=O)O)=CC(C(N2)=O)=C1N=C2CC1=CC=CC(Cl)=C1 OHWZRDHRORANHY-UHFFFAOYSA-N 0.000 claims 2
- NZPFNMZJSZYNLZ-UHFFFAOYSA-N 2-[(3-chlorophenyl)methyl]-5-methyl-4-oxo-3h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1C(=O)C=2C(C)=C(C(O)=O)SC=2N=C1CC1=CC=CC(Cl)=C1 NZPFNMZJSZYNLZ-UHFFFAOYSA-N 0.000 claims 2
- PREAJIFBSWKBRL-UHFFFAOYSA-N 2-[(5-chloro-2-fluorophenyl)methyl]-5-methyl-4-oxo-3h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1C(=O)C=2C(C)=C(C(O)=O)SC=2N=C1CC1=CC(Cl)=CC=C1F PREAJIFBSWKBRL-UHFFFAOYSA-N 0.000 claims 2
- MNNQGRJYHHDZPP-UHFFFAOYSA-N 2-benzyl-4-oxo-3h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound S1C(C(=O)O)=CC(C(N2)=O)=C1N=C2CC1=CC=CC=C1 MNNQGRJYHHDZPP-UHFFFAOYSA-N 0.000 claims 2
- IJHOVPDESGUYIJ-UHFFFAOYSA-N 4-oxo-2-(thiophen-2-ylmethyl)-3h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound S1C(C(=O)O)=CC(C(N2)=O)=C1N=C2CC1=CC=CS1 IJHOVPDESGUYIJ-UHFFFAOYSA-N 0.000 claims 2
- LIQNVZZWECMHPS-UHFFFAOYSA-N 5-methyl-4-oxo-2-[[3-(trifluoromethyl)phenyl]methyl]-3h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound N1C(=O)C=2C(C)=C(C(O)=O)SC=2N=C1CC1=CC=CC(C(F)(F)F)=C1 LIQNVZZWECMHPS-UHFFFAOYSA-N 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000005530 alkylenedioxy group Chemical group 0.000 claims 2
- 125000006620 amino-(C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000004995 haloalkylthio group Chemical group 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims 2
- PZXOKIIUCOXTAT-UHFFFAOYSA-N 4-oxo-2-[[3-(trifluoromethyl)phenyl]methyl]-3h-thieno[2,3-d]pyrimidine-6-carboxylic acid Chemical compound S1C(C(=O)O)=CC(C(N2)=O)=C1N=C2CC1=CC=CC(C(F)(F)F)=C1 PZXOKIIUCOXTAT-UHFFFAOYSA-N 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 241000320892 Clerodendrum phlomidis Species 0.000 claims 1
- 208000009378 Low Cardiac Output Diseases 0.000 claims 1
- 241000287463 Phalacrocorax Species 0.000 claims 1
- 229940083712 aldosterone antagonist Drugs 0.000 claims 1
- 239000002170 aldosterone antagonist Substances 0.000 claims 1
- 229940125365 angiotensin receptor blocker-neprilysin inhibitor Drugs 0.000 claims 1
- 229940126905 angiotensin receptor-neprilysin inhibitor Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 229940097320 beta blocking agent Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 206010007625 cardiogenic shock Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- RBNBDIMXFJYDLQ-UHFFFAOYSA-N thieno[3,2-d]pyrimidine Chemical class C1=NC=C2SC=CC2=N1 RBNBDIMXFJYDLQ-UHFFFAOYSA-N 0.000 claims 1
- -1 thienopyrimidine compound Chemical class 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359695P | 2016-07-07 | 2016-07-07 | |
| US62/359,695 | 2016-07-07 | ||
| PCT/US2017/041249 WO2018009899A1 (en) | 2016-07-07 | 2017-07-07 | Methods for treatment of heart failure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019521192A JP2019521192A (ja) | 2019-07-25 |
| JP2019521192A5 true JP2019521192A5 (enExample) | 2020-08-13 |
Family
ID=60912319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019520937A Pending JP2019521192A (ja) | 2016-07-07 | 2017-07-07 | 心不全の処置方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10870656B2 (enExample) |
| EP (1) | EP3481399A4 (enExample) |
| JP (1) | JP2019521192A (enExample) |
| KR (1) | KR20190049691A (enExample) |
| AU (1) | AU2017292918B2 (enExample) |
| CA (1) | CA3030021A1 (enExample) |
| WO (1) | WO2018009899A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020010884A (es) | 2018-04-17 | 2021-02-26 | Cardurion Pharmaceuticals Llc | Sales de meglumina de tienopirimidinas. |
| AU2020235187B8 (en) * | 2019-03-08 | 2024-02-08 | Transthera Sciences (Nanjing), Inc. | Uses of phosphodiesterase inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| CN101106997A (zh) * | 2004-08-17 | 2008-01-16 | 约翰·霍普金斯大学 | Pde5抑制剂组合物及治疗心脏病征候的方法 |
| US8293754B2 (en) * | 2005-06-14 | 2012-10-23 | Aska Pharmaceutical Co., Ltd. | Thienopyrimidine derivatives |
| WO2007127175A2 (en) * | 2006-04-26 | 2007-11-08 | F. Hoffmann-La Roche Ag | Pharmaceutical compounds |
| GB2465405A (en) * | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| BR112012030689B1 (pt) * | 2010-05-31 | 2021-11-09 | Aska Pharmaceutical Co., Ltd. | Cristal de derivado de tienopirimidina, medicamento, composição farmacêutica e método de produção e uso do cristal |
| MX2016004250A (es) * | 2013-10-07 | 2016-07-12 | Bayer Pharma AG | Tienouracilcarboxamidas ciclicas y usos de las mismas. |
-
2017
- 2017-07-07 EP EP17825050.2A patent/EP3481399A4/en not_active Withdrawn
- 2017-07-07 CA CA3030021A patent/CA3030021A1/en not_active Abandoned
- 2017-07-07 WO PCT/US2017/041249 patent/WO2018009899A1/en not_active Ceased
- 2017-07-07 AU AU2017292918A patent/AU2017292918B2/en active Active
- 2017-07-07 JP JP2019520937A patent/JP2019521192A/ja active Pending
- 2017-07-07 KR KR1020197003599A patent/KR20190049691A/ko not_active Ceased
-
2019
- 2019-01-04 US US16/240,393 patent/US10870656B2/en active Active
-
2020
- 2020-12-21 US US17/128,584 patent/US20210261567A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523974A5 (enExample) | ||
| US10131671B2 (en) | Organic compounds | |
| JP2014518882A5 (enExample) | ||
| JP2016528197A5 (enExample) | ||
| JP2016530283A5 (enExample) | ||
| WO2019143902A3 (en) | Substituted heterocycles as antiviral agents | |
| JP2006505581A5 (enExample) | ||
| RU2016129472A (ru) | Бициклические гетероциклические соединения и их применение в терапии | |
| JP2013528640A5 (enExample) | ||
| EA200600190A1 (ru) | Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона | |
| JP2018527295A5 (enExample) | ||
| EP3848026A1 (en) | Combinations and methods comprising a capsid assembly inhibitor | |
| RU2015108898A (ru) | 3-ЦИКЛОГЕКСЕНИЛ И ЦИКЛОГЕКСИЛ ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ И ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ | |
| RU2014141579A (ru) | Гетероциклические соединения в качестве ингибиторов бета-лактамаз | |
| JP2017528498A5 (enExample) | ||
| RU2012117796A (ru) | Производные пиразолиндиона как ингибиторы надфн-оксидазы | |
| RU2006122209A (ru) | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы | |
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| JP2013542996A5 (enExample) | ||
| RU2006133898A (ru) | Производные бензимидазола и его применение | |
| RU2014120373A (ru) | Соединения азетидина, композиции и их применение в качестве ингибиторов растворимой эпоксидгидролазы | |
| RU2011144763A (ru) | 6-(3-азабицикло[3.1.0]гекс-3-ил)-2-фенилпиримидины | |
| RU2012134510A (ru) | Применение агента, обладающего модифицирующими свойствами в отношении гормонов надпочечников | |
| JP2012510957A5 (enExample) | ||
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 |